Related Experiment Video
Updated: Jun 20, 2026

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
Published on: April 5, 2011
Reversible intraventricular conduction defect in aconitine poisoning
1Hong Kong Poison Information Centre, United Christian Hospital, 130 Hip Wo Street, Kwun Tong, Hong Kong. anfernee_yim@hotmail.com
Processed Fuzi, a Chinese medicine herb, can cause dangerous heart rhythm problems like ventricular arrhythmias due to its narrow therapeutic index. This case highlights reversible intraventricular conduction defects linked to its use.
Area of Science:
- Cardiology
- Integrative Medicine
- Pharmacology
Background:
- Chinese medicine, including the herb aconite (processed Fuzi), is widely used in Hong Kong.
- Aconite has a narrow therapeutic index, increasing the risk of toxicity.
- Cardiac arrhythmias, such as ventricular arrhythmias, are known potential toxicities.
Observation:
- A 57-year-old woman presented with cardiac issues.
- Her condition was linked to the consumption of processed Fuzi.
- The patient experienced a reversible intraventricular conduction defect.
Findings:
- Processed Fuzi can induce serious cardiac adverse events.
- Intraventricular conduction defects are a potential manifestation of aconite toxicity.
- The cardiac abnormality in this case was reversible upon cessation of the herb.
Implications:
- Clinicians should be aware of potential cardiac toxicities associated with Chinese herbal medicine like processed Fuzi.
- Prompt recognition and management are crucial for reversible conditions.
- Further research into the safe use and monitoring of potent herbal ingredients is warranted.
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
